Tocris Bioscience™ CG 858
Selective BRAF-V600E protein Degrader (uSMITE™)
Manufacturer: Tocris Bioscience™ 7427/5
DescriptionCG 858 is a selective BRAF-V600E protein Degrader (uSMITETM). CG 858 comprises the BRAF kinase inhibitor vemurafenib linked to the E3 ligase ligand Thalidomide (Cat. No. 0652). CG 858 dose-dependently degrades BRAF-V600E but not wild type BRAF, and reduces cell viability and colony formation in HT-29 and A375 cells (DC50 values are 124 nM and 500 nM, respectively). Exhibits 88% degradation at 500 nM. CG 858 also impairs melanoma cell growth.
CG 858 negative control (Cat. No. 7428) also available.
|N-[[4-[3-[2,6-Difluoro-3-[(propylsulfonyl)amino]benzoyl]-1 H-pyrrolo[2,3-b]pyridin-5-yl]phenyl]methyl]-5-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1 H-isoindol-5-yl]amino]pentanamide|
Safety and Handling
Recommended Storage : Store at -20°C
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.